Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Charlotte Hedin, Gina Sado, Nelson Ndegwa, Ellina Lytvyak, Andrew L. Mason, Aldo J. Montaño‐Loza, Alessio Gerussi, Francesca Saffioti, Douglas Thorburn, Emma Nilsson, Geir Larsson, Bjørn Moum, Kim N. van Munster, Cyriel Y. Ponsioen, Cynthia Levy, Nicholas Fonseca Nogueira, Christopher L. Bowlus, Neta Gotlieb, Oren Shibolet, Kate D. Lynch, Roger W. Chapman, Christian Rupp, Mette Vesterhus, Kristin Kaasen Jørgensen, Fredrik Rorsman, Christoph Schramm, João Sabino, Séverine Vermeire, Alessandra Zago, Nora Cazzagon, Hanns–Ulrich Marschall, Henriette Ytting, Karima Ben Belkacem, Olivier Chazouillères, Sven Almér, Annika Bergquist
Topics & Concepts
MedicineAdalimumabInterquartile rangeInfliximabPrimary sclerosing cholangitisInternal medicineGastroenterologyDiscontinuationCalprotectinUlcerative colitisTumor necrosis factor alphaInflammatory bowel diseaseRetrospective cohort studyDiseaseLiver Diseases and ImmunityPancreatitis Pathology and TreatmentGallbladder and Bile Duct Disorders